<SEC-DOCUMENT>0001193125-21-357355.txt : 20211215
<SEC-HEADER>0001193125-21-357355.hdr.sgml : 20211215
<ACCEPTANCE-DATETIME>20211215064359
ACCESSION NUMBER:		0001193125-21-357355
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20211215
FILED AS OF DATE:		20211215
DATE AS OF CHANGE:		20211215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AEGON NV
		CENTRAL INDEX KEY:			0000769218
		STANDARD INDUSTRIAL CLASSIFICATION:	LIFE INSURANCE [6311]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10882
		FILM NUMBER:		211493049

	BUSINESS ADDRESS:	
		STREET 1:		AEGONPLEIN 50
		STREET 2:		PO BOX 85
		CITY:			THE HAGUE
		STATE:			P7
		ZIP:			2501 CB
		BUSINESS PHONE:		011-31-70-344-7308

	MAIL ADDRESS:	
		STREET 1:		AEGONPLEIN 50
		STREET 2:		PO BOX 85
		CITY:			THE HAGUE
		STATE:			P7
		ZIP:			2501 CB
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d274764d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Securities and Exchange Commission
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or 15d/16 of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;15, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Aegon N.V.
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aegonplein 50 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2591 TV
THE HAGUE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aegon&#146;s press release, dated December&nbsp;15, 2021, is included as appendix and incorporated herein by
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aegon N.V.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: &nbsp;&nbsp;December&nbsp;15, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J.O. van Klinken</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.O. van Klinken</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Executive Vice President and</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Counsel</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g274764dsp000.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><FONT COLOR="#0077c7">Aegon reinsures more longevity exposure in the Netherlands </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Aegon today announces that it has reinsured an additional part of its longevity exposure in the Netherlands with Reinsurance Group of America, Incorporated (RGA). This
transaction improves the risk profile of the Dutch Life business and releases capital at attractive terms. As a result of actions taken over the past year, Aegon expects to increase the regular remittances from this business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The reinsurance agreement provides protection against the longevity risk associated with EUR&nbsp;7&nbsp;billion of pension liabilities. The risk transfer is effective
per December&nbsp;31, 2021 and will continue until the reinsured block of business has run off in full. The transaction includes deferred pensioners as well as <FONT STYLE="white-space:nowrap">in-payment</FONT> policies of pensioners and dependents,
leading to a very long <FONT STYLE="white-space:nowrap">run-off</FONT> period. This reinsurance protects Aegon against the potential adverse financial impact of longevity risk over the full life of the policies at an attractive cost of capital. The
transaction follows a similar longevity reinsurance structure executed by Aegon in December 2019. Together, these agreements mitigate approximately 40% of the longevity risk exposure of the Dutch life business. These reinsurance agreements have no
impact on the services and guarantees that Aegon provides to its policyholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&#147;This longevity reinsurance agreement is another bilateral action taken to
maximize the value of our Dutch Life business,&#148; says Lard Friese, CEO of Aegon N.V. &#147;In line with our strategy, this builds on actions we have previously taken to improve the risk profile of this business and is another step to generate
stable, regular, and reliable cash flows from the Dutch Life business.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The benefit to the Dutch Life business Solvency&nbsp;II ratio is expected to be around
<FONT STYLE="white-space:nowrap">15%-points.</FONT> This corresponds to an approximate 5%-point increase in the Group&#146;s Solvency II ratio. Operating capital generation of the Dutch Life business will initially be reduced by
EUR&nbsp;40&nbsp;million per year and the IFRS operating result will decrease by less than EUR&nbsp;15&nbsp;million per year. The impact on operating capital generation and the operating result will decrease over time in line with the maturity of
the reinsured portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Aegon expects to increase the regular quarterly remittances of the Dutch Life business from EUR&nbsp;25&nbsp;million to
EUR&nbsp;50&nbsp;million per quarter as of the first quarter of 2022. This follows management actions taken over the past year to strengthen the capital position, improve the risk profile, and increase capital generation. </P>
<P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #0077c7">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Aegon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Aegon&#146;s roots go back more than 175 years &#150; to the first
half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in the Americas, Europe, and Asia. Today, Aegon is one of the world&#146;s leading financial services organizations, providing life insurance,
pensions, and asset management. Aegon&#146;s purpose is to help people achieve a lifetime of financial security. More information on <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#0077c7">aegon.com</FONT><FONT
STYLE="font-family:ARIAL; font-size:9pt" COLOR="#0077c7">.</FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Contacts</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom">Media relations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Investor relations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"><FONT COLOR="#0077c7"><B>Dick Schiethart</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#0077c7"><B>Jan Willem Weidema</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom">+31(0) 70 344 8821</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+31(0) 70 344 8028</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"><FONT COLOR="#0077c7">dick.schiethart@aegon.com</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#0077c7">janwillem.weidema@aegon.com</FONT></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g274764dsp000.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Forward-looking statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The
statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim,
believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements are not
guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and
uncertainties. Such risks and uncertainties include but are not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in general economic and/or governmental conditions, particularly in the United States, the Netherlands and the
United Kingdom; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in the performance of financial markets, including emerging markets, such as with regard to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The frequency and severity of defaults by issuers in Aegon&#146;s fixed income investment portfolios;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in
the value of equity and debt securities Aegon holds; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of
government exposure that Aegon holds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in the performance of Aegon&#146;s investment portfolio and decline in ratings of Aegon&#146;s counterparties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Lowering of one or more of Aegon&#146;s debt ratings issued by recognized rating organizations and the adverse impact such
action may have on Aegon&#146;s ability to raise capital and on its liquidity and financial condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Lowering of one or more of insurer financial strength ratings of Aegon&#146;s insurance subsidiaries and the adverse impact
such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The effect of the European Union&#146;s Solvency II requirements and other regulations in other jurisdictions affecting the
capital Aegon is required to maintain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as
well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war
and pandemics, could result in material losses and significantly interrupt Aegon&#146;s business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The frequency and severity of insured loss events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of
Aegon&#146;s insurance products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Aegon&#146;s projected results are highly sensitive to complex mathematical models of financial markets, mortality,
longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary
from projected results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon
sells, including legal, regulatory or commercial necessity to meet changing customer expectations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Customer responsiveness to both new products and distribution channels; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">As Aegon&#146;s operations support complex transactions and are highly dependent on the proper functioning of information
technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls
including with respect to third parties with which we do business may disrupt Aegon&#146;s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including
Aegon&#146;s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Aegon&#146;s failure to achieve anticipated levels of earnings or operational efficiencies, as well as other management
initiatives related to cost savings, cash capital at Holding, gross financial leverage and free cash flow; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in the policies of central banks and/or governments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for
Aegon&#146;s products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Consequences of an actual or potential <FONT STYLE="white-space:nowrap">break-up</FONT> of the European monetary union in
whole or in part, or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in laws and regulations, particularly those affecting Aegon&#146;s operations&#146; ability to hire and retain key
personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon
operates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the
International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the
designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer <FONT STYLE="white-space:nowrap">(G-SII);</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily
or otherwise, which may affect Aegon&#146;s reported results, shareholders&#146; equity or regulatory capital adequacy levels. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Further details of
potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements
speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in Aegon&#146;s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g274764dsp000.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g274764dsp000.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MK=E^/^8?\+<U_P#Y]-/_ ._;_P#Q=']FT>[_  _R#^U:W9?C_F'_  MS7_\
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M_P @_M6MV7X_YA_PMS7_ /GTT_\ []O_ /%T?V;1[O\ #_(/[5K=E^/^8?\
M"W-?_P"?33_^_;__ !=']FT>[_#_ "#^U:W9?C_F'_"W-?\ ^?33_P#OV_\
M\71_9M'N_P /\@_M6MV7X_YA_P +<U__ )\]/_[]O_\ %T?V91[O\/\ (?\
M:E;LOQ_S#_A;FO\ _/II_P#W[?\ ^+H_LVCW?X?Y"_M6MV7X_P"8?\+<U_\
MY]-/_P"_;_\ Q=']FT>[_#_(/[5K=E^/^8?\+<U[_GTT_P#[]O\ _%T?V;1[
MO\/\@_M6MV7X_P"8'XN:_P!K33_^_;__ !=']F4>[_#_ "#^U:W9?C_F'_"W
M-?\ ^?33_P#OV_\ \71_9M'N_P /\@_M6MV7X_YA_P +<U[_ )]-/_[]O_\
M%TO[-I=W^'^0?VI6[+\?\S=\)?$>^UG6%LM1BM8E<?(8D8$G\6-<V)P,*4.:
M%SIPV83JSY9I?U\STD&O)1[(M, H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M\M^,G_,%_P"VW_LE>SE?V_E^IXF;?8^?Z'EE>P>('TH$ Z4 % T% !0 4" ^
MU 6"@!: "@ H ;WH 44 +0 E "T % !0 E "T '2@ H 0B@ -  .E  * L+0
M 4 % "4 +0 4 % "4 % PH!BT""@ H * "@ H * $H'L'% "T""@ H 2@$%!
M04"#F@0M !0 4 % "4 % Q:!!0 AZ4  H 6@!*0RQ8W;V-]!=1$AXF##%3.*
ME%IEPDXR31](:5>IJ&EVUTAR)(PWZ5\I4AR3<3ZZE-3@I%VH-0H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H .E !FE<!,BF M !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 >6_&3_F"_P#;;_V2O9RO[?R_4\3-OL?/
M]#RRO8/$%I""F E T% "T"$H&% PH$ H$+2 2F-!0 4A!3 .E(!: "F 4 %
M!0"$H*"@!:"6% !0 E!0M!(4 % " 8H 6@ H 3M0 "@ H&% ,,T""@H6@D*
M"@ H 2@8M ,*!!0 4 % !0"$H*%H)"@ H * $H&+0#"@0@XXH  : %H * 0E
M!04 %  ."#Z4"/9/A=K/VK27TZ1OGMS\@]J\#,*/+/F1]%EU;FAR/<]!KS3U
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H #0!%+/'
MA>5U1!U9C@"A)RT2)E*,=6SD]3^)'A[3F:-+A[N5>T"Y7_OH\?E7;3P-:6Z.
M*KCZ-->Z[G0Z'JT6N:-;:C"I5)USM/53T(_ URU*;I2<6=5*HJL%)&A4&H4
M% !0 4 % !0 4 % !0 4 % !0 4 >6_&3_F"_P#;;_V2O9RO[?R_4\3-OL?/
M]#RRO8/$%H$']*6B=V.S:L@]L5/.D]RE%_T@Q5$KL)3 6@0E T% !TH$+0 G
M2@!: "@!T44D\JQ0QM)(QPJ(,DGT J9248MOH.*<I**$='CD:-U*.I(8$8((
M[4*2DDT.2Y782F2%, H 2@:"@ [T#"@ H$% "T""@ H * $S0 O2@ H * "@
M H * "@ Q0 4 % !0 4 % !0 4 % !0 4 )0-!0 M @Z4 )D4 +0 4 % !0
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M$J-7=E\S/U32;S1KQK6^B\N4 $8.0P]0>XK6G6A45XF56C*E+ED4JVV,+BT
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M/)M"O9+C]GOQ%;.25MKI53/0 O&V/S)_.@9S6D0:GX0L="\;V+%X997BD3.
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M/F$A@?4'!H \6N+"_P!&\96NB7[L_P#9]XL<8/0*7SD>Q^]^- SZY'4T"%H
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M&3QBNJDZC7[Q6.&K&E'X'<IBMS'86@ H * "D 4#$H *8Q:"0H * "@ H *
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M"4  XH&@H !0 M @H * $H&+0(* "@ H 2D,6F(* "@ H * "@ H * "@ H
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M "T )0 9% !Q0 Y'*,&4X(.10US)H:?*U)'O?A+Q':7_ (?MGGNX4F1=KAW
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M_MO^_J_XT<DNP>TAW#^U=._Y_P"V_P"_J_XT<DNP>TAW#^U=._Y_[;_OZO\
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MQ_S'_9='N_P_R#_A4>@?\_>H?]_$_P#B*/[2K=E^/^8O[*H]W^'^0?\ "H]
M_P"?O4/^_B?_ !%']I5NR_'_ ##^RJ/=_A_D'_"H] _Y^]0_[^)_\11_:57L
MOQ_S#^RJ/=_A_D'_  J/0/\ G[U#_OXG_P 11_:57LOQ_P P_LJCW?X?Y!_P
MJ/0/^?O4/^_B?_$4?VE6[+\?\P_LJCW?X?Y!_P *CT#_ )^]0_[^)_\ $4?V
ME6[+\?\ ,/[*H]W^'^0?\*CT#_G\U#_OXG_Q%']I5NR_'_,/[*H]W^'^0?\
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M1_:57LOQ_P P_LJCW?X?Y!_PJ/0/^?O4/^_B?_$4?VE6[+\?\Q_V71[O\/\
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M8?V51[O\/\@_X5%H'_/YJ/\ W\3_ .(H_M.MV7X_YA_95'N_P_R#_A46@?\
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MNR_'_,/[*H]W^'^0?\*BT#_G\U'_ +^)_P#$4?VE6[+\?\P_LJCW?X?Y"?\
M"HM _P"?S4?^_B?_ !%']I5NR_'_ ##^RJ/=_A_D+_PJ+0/^?S4?^_B?_$4_
M[3K=E^/^8?V51[O\/\@_X5%H'_/YJ/\ W\3_ .(H_M.MV7X_YA_95'N_P_R$
M/PBT _\ +YJ/_?Q/_B*7]I5>R_'_ #'_ &71VN_P_P @_P"%0Z!_S^:C_P!_
M(_\ XBG_ &E5_E7X_P"8?V51[O\ #_(/^%0Z!_S^:C_W\C_^(H_M*K_*OQ_S
M#^RJ/=_A_D'_  J'0/\ G\U'_OY'_P#$4?VE5_E7X_YA_95'N_P_R#_A4.@?
M\_FH_P#?R/\ ^(H_M*K_ "K\?\P_LJCW?X?Y!_PJ'0/^?S4?^_D?_P 11_:5
M7^5?C_F']E4>[_#_ "#_ (5#H'_/YJ/_ '\C_P#B*/[2J_RK\?\ ,/[*H]W^
M'^0?\*AT#_G\U'_OY'_\11_:57^5?C_F']E4>[_#_(/^%0Z!_P _FH_]_(__
M (BC^TJO\J_'_,/[*H]W^'^0?\*AT#_G\U'_ +^1_P#Q%']I5?Y5^/\ F']E
M4>[_  _R#_A4.@?\_FH_]_(__B*/[2J_RK\?\P_LJCW?X?Y!_P *AT#_ )_-
M1_[^1_\ Q%']I5?Y5^/^8?V51[O\/\@_X5#H'_/YJ/\ W\C_ /B*/[2J_P J
M_'_,/[*H]W^'^0?\*AT#_G\U'_OY'_\ $4?VE5_E7X_YA_95'N_P_P @_P"%
M0Z!_S^:C_P!_(_\ XBC^TJO\J_'_ ##^RJ/=_A_D'_"H= _Y_-1_[^1__$4?
MVE5_E7X_YA_95'N_P_R#_A4.@?\ /YJ/_?R/_P"(H_M*K_*OQ_S#^RJ/=_A_
MD'_"H= _Y_-1_P"_D?\ \11_:57^5?C_ )A_95'N_P /\@_X5#H'_/YJ/_?R
M/_XBC^TJO\J_'_,/[*H]W^'^0?\ "H= _P"?S4?^_D?_ ,11_:57^5?C_F']
ME4>[_#_(/^%0Z!_S^:C_ -_(_P#XBC^TJO\ *OQ_S#^RJ/=_A_D'_"H= _Y_
M-1_[^1__ !%']I5?Y5^/^8?V51[O\/\ (/\ A4.@?\_FH_\ ?R/_ .(H_M*K
M_*OQ_P P_LJCW?X?Y!_PJ'0/^?S4?^_D?_Q%']I5?Y5^/^8?V51[O\/\@_X5
M#H'_ #^:C_W\C_\ B*/[2J_RK\?\P_LJCW?X?Y!_PJ'0/^?S4?\ OY'_ /$4
M?VE5_E7X_P"8?V51[O\ #_(/^%0Z!_S^:C_W\C_^(H_M*K_*OQ_S#^RJ/=_A
M_D'_  J'0/\ G\U'_OY'_P#$4?VE5_E7X_YA_95'N_P_R#_A4.@?\_FH_P#?
MR/\ ^(H_M*K_ "K\?\P_LJCW?X?Y!_PJ'0/^?S4?^_D?_P 11_:57^5?C_F'
M]E4>[_#_ "#_ (5#H'_/YJ/_ '\C_P#B*/[2J_RK\?\ ,/[*H]W^'^0?\*AT
M#_G\U'_OY'_\11_:57^5?C_F']E4>[_#_(/^%0Z!_P _FH_]_(__ (BC^TJO
M\J_'_,/[*H]W^'^0?\*AT#_G\U'_ +^1_P#Q%']I5?Y5^/\ F']E4>[_  _R
M#_A4.@?\_FH_]_(__B*/[2J_RK\?\P_LJCW?X?Y!_P *AT#_ )_-1_[^1_\
MQ%']I5?Y5^/^8?V51[O\/\@_X5#H'_/YJ/\ W\C_ /B*/[2J_P J_'_,/[*H
M]W^'^18L/A;HFGZA;7L5U?F2WE650TB8)4@C/R].*B>85)Q<6EKZ_P"94,MH
MPDI)O3^NQV]>>>D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M-JT\?C&TT@)']GFLI;AF(.X,KHH .<8PY[>E$5=2?:WXW_R%)VY?._X6*?\
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MRCY.!U]<= HJ\')]_P!+ES7*U;K?\+?YG1TA!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MR'.%.2<OM[<=:TG+WIU(]59+U:>OI8SA"T(TV]FKOR2?YECPP-8DU;^T=?\
M#M_'JEPOEM.TEL8+5.OEH%E+X) R=N6.,X   K)-)_\ !_KHOU*=V[OIM_7?
MN;%OIUU'XZOM2:+%I+80PI)N'+J\A(QUZ,/SJ8Z0DO/]"YNZC;I?\;?Y&[2)
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H BN;:WO+:2VNH(YX)!M>.10RL/0@\&DTGN--IW1#
MI^EZ?I-M]FTVQMK*#.?+MXEC7/KA0!5-MDV2+=(84 % !0 4 % !0 4 % !0
M 4 % !0 4 -=%D1D=0R,,%2,@CTH:OH-.VJ%5510J@*H&  , 4;B2MHA: "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
5 * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
